Kolject (Colistimethate Sodium)

Colistimethate sodium binds to lipopolysaccharides and phospholipids in the outer membrane of Gram‑negative bacteria, displacing essential cations. This disrupts membrane integrity, increases permeability, and leads to leakage of cellular contents, ultimately causing bacterial cell death.

The dose of Kolject is individualized by the prescribing clinician based on infection severity, pathogen susceptibility, patient weight, and renal function. Dosage regimens are determined in a hospital setting and adjusted according to therapeutic response and safety monitoring.

Safety data for colistimethate sodium in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To order Kolject, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Kolject (colistimethate sodium) is a pro‑drug of colistin, offering similar antibacterial spectrum to polymyxin B but is administered intravenously as a sterile solution. Compared with polymyxin B, colistimethate sodium may have a higher risk of nephrotoxicity, while both share neurotoxic potential; selection depends on clinical context and susceptibility data.

Kolject must be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Before administration, allow the solution to reach room temperature if required, and inspect for particulate matter or discoloration; discard if any abnormalities are observed.

Kolject is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are determined by the prescribing physician, typically over a period of 30‑60 minutes, with appropriate monitoring of renal function and electrolytes during treatment.

The most serious adverse events associated with Kolject include acute renal failure, severe neurotoxicity such as neuromuscular blockade leading to respiratory compromise, and rare hypersensitivity reactions like anaphylaxis. Prompt recognition and discontinuation are essential if these events occur.

Kolject should be avoided in patients with known hypersensitivity to colistimethate sodium or any component of the formulation, and in individuals with pre‑existing severe renal impairment unless dose adjustments are made. Caution is also advised for patients receiving other nephrotoxic or neurotoxic agents.